Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Akebia Therapeutics, Inc. |
|---|---|
| Ticker | AKBA |
| CIK | 0001517022 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 381,7 Mio. USD |
| Beta | 0,37 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 236,196,000 | -5,345,000 | -0.02 | 376,565,000 | 32,610,000 |
| 2025-09-30 | 10-Q | 58,766,000 | 540,000 | 0.00 | 364,152,000 | 41,592,000 |
| 2025-06-30 | 10-Q | 62,472,000 | 247,000 | 0.00 | 345,595,000 | 29,224,000 |
| 2025-03-31 | 10-Q | 57,336,000 | 6,112,000 | 0.03 | 310,185,000 | 24,581,000 |
| 2024-12-31 | 10-K | 160,180,000 | -69,410,000 | -0.33 | 220,670,000 | -49,185,000 |
| 2024-09-30 | 10-Q | 37,428,000 | -20,039,000 | -0.10 | 207,142,000 | -50,402,000 |
| 2024-06-30 | 10-Q | 43,648,000 | -8,582,000 | -0.04 | 220,196,000 | -33,754,000 |
| 2024-03-31 | 10-Q | 32,607,000 | -17,985,000 | -0.09 | 225,477,000 | -27,258,000 |
| 2023-12-31 | 10-K | 194,623,000 | -51,925,000 | -0.28 | 241,703,000 | -30,584,000 |
| 2023-09-30 | 10-Q | 42,046,000 | -14,489,000 | -0.08 | 234,998,000 | -39,420,000 |
| 2023-06-30 | 10-Q | 56,376,000 | -11,172,000 | -0.06 | 253,712,000 | -26,805,000 |
| 2023-03-31 | 10-Q | 40,005,000 | -26,876,000 | -0.15 | 280,928,000 | -19,123,000 |
| 2022-12-31 | 10-K | 292,484,000 | -94,226,000 | -0.52 | 356,054,000 | 5,230,000 |
| 2022-09-30 | 10-Q | 48,714,000 | -54,096,000 | -0.29 | 435,894,000 | 8,259,000 |
| 2022-06-30 | 10-Q | 126,365,000 | 29,449,000 | 0.15 | 529,882,000 | 58,937,000 |
| 2022-03-31 | 10-Q | 61,699,000 | -63,509,000 | -0.35 | 541,799,000 | 22,580,000 |
| 2021-12-31 | 10-Q | -282,024,000 | 525,550,000 | 74,008,000 | ||
| 2021-12-31 | 10-K | 213,578,000 | -282,840,000 | -1.70 | 525,550,000 | 74,008,000 |
| 2021-09-30 | 10-Q | 48,756,000 | -59,544,000 | -0.34 | 602,267,000 | 137,150,000 |
| 2021-06-30 | 10-Q | 52,913,000 | -83,038,000 | -0.51 | 611,863,000 | 174,631,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Butler John P. | Director, Officer, CEO and President | Open Market Purchase | 69,270 | 1.25 | 86,587.50 | +129,2% | |
| 2026-02-02 | Malabre Richard C | Officer, SVP, Chief Accounting Officer | Open Market Sale | -13,382 | 1.39 | -18,600.98 | -27,8% | |
| 2026-02-02 | Malabre Richard C | Officer, SVP, Chief Accounting Officer | Open Market Sale | -36,142 | 1.39 | -50,237.38 | -75,0% | |
| 2026-02-02 | Grund Nicholas | Officer, Chief Commercial Officer | Open Market Sale | -31,244 | 1.39 | -43,429.16 | -64,8% | |
| 2026-02-02 | Grund Nicholas | Officer, Chief Commercial Officer | Open Market Sale | -53,585 | 1.39 | -74,483.15 | -111,2% | |
| 2026-02-02 | Burke Steven Keith | Officer, SVP, Chief Medical Officer | Open Market Sale | -20,701 | 1.39 | -28,774.39 | -42,9% | |
| 2026-02-02 | Burke Steven Keith | Officer, SVP, Chief Medical Officer | Open Market Sale | -21,582 | 1.39 | -29,998.98 | -44,8% | |
| 2026-02-02 | Burke Steven Keith | Officer, SVP, Chief Medical Officer | Open Market Sale | -25,375 | 1.39 | -35,271.25 | -52,6% | |
| 2026-02-02 | Rucci Carolyn M. | Officer, SVP, Chief Legal Officer | Open Market Sale | -25,382 | 1.39 | -35,280.98 | -52,7% | |
| 2026-02-02 | Rucci Carolyn M. | Officer, SVP, Chief Legal Officer | Open Market Sale | -27,544 | 1.39 | -38,286.16 | -57,1% | |
| 2026-02-02 | Ostrowski Erik | Officer, SVP, CFO, CBO & Treasurer | Open Market Sale | -34,951 | 1.39 | -48,581.89 | -72,5% | |
| 2026-02-02 | Butler John P. | Director, Officer, CEO and President | Open Market Sale | -46,660 | 1.39 | -64,857.40 | -96,8% | |
| 2026-02-02 | Butler John P. | Director, Officer, CEO and President | Open Market Sale | -83,689 | 1.39 | -116,327.71 | -173,6% | |
| 2026-02-02 | Butler John P. | Director, Officer, CEO and President | Open Market Sale | -96,065 | 1.39 | -133,530.35 | -199,3% | |
| 2026-02-02 | Butler John P. | Director, Officer, CEO and President | Open Market Sale | -114,891 | 1.39 | -159,698.49 | -238,4% | |
| 2026-02-02 | Rucci Carolyn M. | Officer, SVP, Chief Legal Officer | Open Market Sale | -16,846 | 1.39 | -23,415.94 | -34,9% | |
| 2025-06-30 | Ostrowski Erik | Officer, SVP, CFO, CBO & Treasurer | Open Market Sale | -41,314 | 3.67 | -151,622.38 | -226,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.